keyword
MENU ▼
Read by QxMD icon Read
search

Sarcomatoid Renal Cell Carcinoma

keyword
https://www.readbyqxmd.com/read/29130016/incidental-eosinophilic-chromophobe-renal-cell-carcinoma-in-renal-allograft
#1
Abdullah Alharbi, Maram S Al Turki, Noura Aloudah, Khaled O Alsaad
The incidence of renal cell carcinoma (RCC) in renal allograft in transplant recipients is 0.22-0.25%. De novo clear cell, papillary, and chromophobe RCCs and RCCs with sarcomatoid differentiation originating in renal allograft have been reported. Routine surveillance for graft tumours is not routinely practiced and these tumours are commonly asymptomatic and incidentally discovered. We describe a case of incidental, eosinophilic chromophobe RCC in a 31-year-old, long-term renal transplant male recipient, who presented with acute gastroenteritis 11 years after transplantation...
2017: Case Reports in Transplantation
https://www.readbyqxmd.com/read/29110685/lingual-metastasis-as-an-initial-presentation-of-renal-cell-carcinoma-a-case-report
#2
Hanan Raiss, Sophie Duplomb, Sophie Tartas, Mohamed Layachi, Hassan Errihani
BACKGROUND: Renal cell carcinoma is the third most common tumor that metastasizes to the head and neck, after breast and lung carcinomas. Tongue metastasis as an initial presentation of renal cell carcinoma is extremely rare, and very few cases have been reported. The prognosis is poor. We present a rare case of metastatic renal cell carcinoma that initially presented as a tongue lesion. CASE PRESENTATION: We report the case of a 55-year-old white man who presented with a large exophytic lesion on his tongue...
November 7, 2017: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/29108268/inherent-characteristics-of-metachronous-metastatic-renal-cell-carcinoma-in-the-era-of-targeted-agents
#3
Jang Hee Han, Seung Hwan Lee, Won Sik Ham, Woong Kyu Han, Koon Ho Rha, Young Deuk Choi, Sung Joon Hong, Young Eun Yoon
Background: To assess the prognostic and predictive factors of time to treatment failure (TTF) and overall survival (OS), respectively, in patients with metachronous metastatic renal cell carcinoma (mRCC) who were treated with targeted agents. Materials and Methods: We retrospectively reviewed metachronous mRCC patients, defined as individuals diagnosed with metastatic disease >3 months after initial nephrectomy, treated at an institute since 2005. Cox proportional hazard regression analysis was performed to discover the most determinant variables associated with TTF and OS...
October 3, 2017: Oncotarget
https://www.readbyqxmd.com/read/29100286/the-pvhl172-isoform-is-not-a-tumor-suppressor-and-up-regulates-a-subset-of-pro-tumorigenic-genes-including-tgfb1-and-mmp13
#4
Pauline Hascoet, Franck Chesnel, Florence Jouan, Cathy Le Goff, Anne Couturier, Eric Darrigrand, Fabrice Mahe, Nathalie Rioux-Leclercq, Xavier Le Goff, Yannick Arlot-Bonnemains
The von Hippel-Lindau (VHL) tumor suppressor gene is often deleted or mutated in ccRCC (clear cell renal cell carcinoma) producing a non-functional protein. The gene encodes two mRNA, and three protein isoforms (pVHL213, pVHL160 and pVHL172). The pVHL protein is part of an E3 ligase complex involved in the ubiquitination and proteasomal degradation of different proteins, particularly hypoxia inducible factors (HIF) that drive the transcription of genes involved in the regulation of cell proliferation, angiogenesis or extracellular matrix remodelling...
September 29, 2017: Oncotarget
https://www.readbyqxmd.com/read/29066509/tumor-microvessel-density-as-a-prognostic-marker-in-high-risk-renal-cell-carcinoma-patients-treated-on-ecog-acrin-e2805
#5
Lucia B Jilaveanu, Maneka Puligandla, Sarah A Weiss, Victoria Xin Wang, Christopher R Zito, Keith T Flaherty, Marta Boeke, Veronique M Neumeister, Robert L Camp, Adebowale Adeniran, Michael Pins, Judith Manola, Robert S DiPaola, Naomi Haas, Harriet M Kluger
PURPOSE: Increased vascularity is a hallmark of renal cell carcinoma (RCC). Microvessel density (MVD) is one measurement of tumor angiogenesis, however its utility as a biomarker of outcome is unknown. ECOG-ACRIN 2805 (E2805) enrolled 1,943 resected high-risk RCC patients randomized to adjuvant sunitinib, sorafenib, or placebo. We aimed to determine the prognostic and predictive role of MVD in RCC. METHODS: We obtained pre-treatment primary RCC nephrectomy tissues from 822 patients on E2805 and constructed tissue microarrays...
October 24, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29036563/loss-of-cd15-expression-in-clear-cell-renal-cell-carcinoma-is-correlated-with-worse-prognosis-in-chinese-patients
#6
Chen-Yan Wu, Jian-Ping Huo, Xin-Ke Zhang, Yi-Jun Zhang, Wan-Ming Hu, Ping Yang, Jia-Bin Lu, Zhi-Ling Zhang, Yun Cao
Purpose: To explore the role of CD15 expression in the prognosis of clear cell renal cell carcinoma (ccRCC) in Chinese patients. Methods: The study included 301 patients who had undergone surgery for localized ccRCC. All paraffin-embedded tumor sections were collected to make a set of tissue microarrays. CD15 expression was assessed by immunohistochemistry. The relationship between CD15 expression and survival parameters, clinicopathology features was assessed. Kaplan-Meier and Cox proportional hazards model were utilized to determine the correlation between CD15 expression and overall survival (OS)...
September 21, 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29034177/rapid-recurrence-and-radiographic-progression-of-sarcomatoid-renal-cell-carcinoma
#7
Mia P Edelson, Wayland J Wu, Anna Kurzyna, Joph Steckel
Sarcomatoid renal cell carcinoma (sRCC) is an aggressive variant of renal cell carcinoma (RCC) that has a significantly lower overall survival. Even after prompt surgical extirpation, this histologic variant progresses rapidly. We present a case of an early recurrence and rapid progression of sRCC despite successful radical resection.
January 2018: Urology Case Reports
https://www.readbyqxmd.com/read/29029447/the-association-between-renal-sinus-fat-area-and-the-progression-free-survival-in-chinese-non-metastatic-clear-cell-renal-cell-carcinoma-patients
#8
Haichao Huang, Shi Chen, Wei Yu, Zirong Ye, Wei Li, Jinchun Xing, Xiurong Wu
In this retrospective study, we evaluated the association between renal sinus fat area (RSFA) and survival in 268 Chinese non-metastatic clear-cell renal cell carcinoma (ccRCC) patients. Patients with high RSFA exhibited better progression-free survival than those with low RSFA in both univariable (HR: 0.240; 95% CI: 0.119-0.482; p < 0.001) and multivariable (HR: 0.432; 95% CI: 0.369-2.749; p = 0.027) analyses. A propensity-score matched (PSM) analysis using Kaplan-Meier curves confirmed our findings (log-rank test; p = 0...
September 12, 2017: Oncotarget
https://www.readbyqxmd.com/read/28963640/development-of-response-classifier-for-vascular-endothelial-growth-factor-receptor-vegfr-tyrosine-kinase-inhibitor-tki-in-metastatic-renal-cell-carcinoma
#9
Heounjeong Go, Mun Jung Kang, Pil-Jong Kim, Jae-Lyun Lee, Ji Y Park, Ja-Min Park, Jae Y Ro, Yong Mee Cho
Vascular endothelial growth factor receptor (VEGFR)-targeted therapy improved the outcome of metastatic renal cell carcinoma (mRCC) patients. However, a prediction of the response to VEGFR-tyrosine kinase inhibitor (TKI) remains to be elucidated. We aimed to develop a classifier for VEGFR-TKI responsiveness in mRCC patients. Among 101 mRCC patients, ones with complete response, partial response, or ≥24 weeks stable disease in response to VEGFR-TKI treatment were defined as clinical benefit group, whereas patients with <24 weeks stable disease or progressive disease were classified as clinical non-benefit group...
September 29, 2017: Pathology Oncology Research: POR
https://www.readbyqxmd.com/read/28938681/high-mucin-5ac-expression-predicts-adverse-postoperative-recurrence-and-survival-of-patients-with-clear-cell-renal-cell-carcinoma
#10
Haijian Zhang, Yidong Liu, Huyang Xie, Weisi Liu, Qiang Fu, Dengfu Yao, Jiejie Xu, Jianxin Gu
BACKGROUND: Mucin 5AC (MUC5AC), as a member of secreted/gel-forming mucin family, was frequently found to be abnormally expressed in inflammation or malignant diseases. However, the clinic pathologic features and prognostic values of MUC5AC in clear-cell renal cell carcinoma (ccRCC) have not been reported up to now. METHODS: MUC5AC expression was analyzed by immunohistochemistry on tissue microarrays. Kaplan-Meier survival curves, Univariate and Multivariate Cox analysis and newly-established nomogram model were performed to evaluate the prognostic value...
August 29, 2017: Oncotarget
https://www.readbyqxmd.com/read/28937382/malignant-fibrous-histiocytoma-arising-from-renal-capsule-an-extremely-rare-entity
#11
Shilpa Bairwa, Ashok Sangwaiya, Mariyam Ansari, Arpita Jindal, Sapna Singla, Ajay Yadav
Malignant fibrous histiocytoma (MFH) usually presents in the extremities or retroperitoneum. MFH arising from renal parenchyma or renal capsule is extremely rare, only few cases have been reported in literature and portend a poor prognosis. Renal MFH is differentiated from renal cell carcinoma, renal sarcoma, and sarcomatoid renal tumor only by histological and immunohistochemical studies. Since the therapeutic options for MFH are different, its early diagnosis is imperative. Herein, we report a case of a primary renal MFH in a 35-year-old male...
July 2017: Indian Journal of Pathology & Microbiology
https://www.readbyqxmd.com/read/28932952/survival-of-metastatic-renal-cell-carcinoma-patients-continues-to-improve-over-time-even-in-targeted-therapy-era
#12
Michele Marchioni, Marco Bandini, Raisa S Pompe, Zhe Tian, Tristan Martel, Anil Kapoor, Luca Cindolo, Francesco Berardinelli, Alberto Briganti, Shahrokh F Shariat, Luigi Schips, Pierre I Karakiewicz
OBJECTIVE: To examine the effect of diagnosis year, defined as contemporary (2010-2014), intermediate (2006-2009) and historical (2001-2005) on cancer-specific mortality (CSM) in patients with metastatic renal cell carcinoma (mRCC). METHODS: Within Surveillance, Epidemiology, and End Results registry (2001-2014), we identified patients with mRCC. Cumulative incidence and competing risks regression (CRR) models examined CSM, after accounting for other-cause mortality...
December 2017: International Urology and Nephrology
https://www.readbyqxmd.com/read/28927783/surgical-resection-of-locally-recurrent-renal-cell-carcinoma-after-nephrectomy-oncological-outcome-and-predictors-of-survival
#13
Roman Herout, Johannes Graff, Angelika Borkowetz, Stefan Zastrow, Steffen Leike, Rainer Koch, Desiree-Louise Draeger, Chris Protzel, Oliver W Hakenberg, Manfred P Wirth, Michael Froehner
OBJECTIVE: To describe the course of disease of patients surgically treated for locally recurrent renal cell carcinoma (LRRCC) after nephrectomy and to identify potential predictive factors for long-term survival. PATIENTS AND METHODS: We, retrospectively, identified 54 patients who underwent surgical resection of LRRCC after open nephrectomy for localized kidney cancer. The median age at time of surgery for LRRCC was 65 years. Survival rates were determined with the Kaplan-Meier method...
September 15, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28912138/sarcomatoid-renal-cell-carcinoma-the-apple-doesn-t-fall-far-from-the-tree
#14
Paulo Bergerot, Neeraj Agarwal, Sumanta K Pal, Jeremy Jones
The most comprehensive sequencing effort of sarcomatoid renal cell carcinoma (sRCC) to date reinforces the notion that the sarcomatoid component is closely related to the epithelial component of the cancer. This work also challenges the notion that sRCC evolves from low-grade RCC and identifies potential mediators of sarcomatoid differentiation. Clin Cancer Res; 23(21); 6381-3. ©2017 AACRSee related article by Wang et al., p. 6686.
November 1, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28892918/sarcomatoid-carcinoma-of-renal-pelvis-with-abundant-heterologous-osteosarcomatous-element-a-case-report
#15
Mona Lisa, Guddi Rani Singh, Richa Madhawi, Bipin Kumar, Zeenat Sarmadi Imam
A 47-year-old male presented with haematuria and flank pain for two weeks. Ultrasonography and renal scan revealed a poorly functioning left kidney with multiple calculi. Simple nephrectomy was performed and the specimen revealed a mass in his renal pelvis which showed both carcinomatous and sarcomatous components on microscopy. The sarcomatous component consisted of diffuse pleomorphic osteoblasts with intervening lacy osteoid, giving an osteosarcoma-like appearance. These areas of tumour were strongly positive for vimentin and osteopontin...
July 2017: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/28890070/oligometastatic-renal-cell-carcinoma-with-sarcomatoid-differentiation-demonstrating-variable-imaging-phenotypes-on-68-ga-psma-and-18-f-fdg-pet-ct-a-case-report-and-review-of-the-literature
#16
David P Nadebaum, Michael S Hofman, Catherine A Mitchell, Shankar Siva, Rodney J Hicks
No abstract text is available yet for this article.
August 23, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28882777/secondary-urethral-malignancies-following-prostate-brachytherapy
#17
Shree Agrawal, John M Lacy, Herman Bagga, Kenneth W Angermeier, Jay Ciezki, Rahul D Tendulkar, Chandana A Reddy, Hadley M Wood
OBJECTIVE: To understand urethral secondary malignancies among patients treated with brachytherapy (BRT) for primary prostate cancer. METHODS: Institutional retrospective review identified 13 patients evaluated from 2003-2014 with urethral cancer and prior history of BRT monotherapy for prostate cancer. All patients were biochemically free of their primary disease and developed histologically distinct RASM from primary tumor via pathologic confirmation. BRT characteristics, patient age, presentation, staging work-up and clinical course were evaluated...
September 4, 2017: Urology
https://www.readbyqxmd.com/read/28870517/phase-2-trial-of-capecitabine-gemcitabine-and-bevacizumab-in-sarcomatoid-renal-cell-carcinoma
#18
Abhishek Maiti, Maryam Nemati-Shafaee, Pavlos Msaouel, Lance C Pagliaro, Eric Jonasch, Nizar M Tannir, Amishi Y Shah
BACKGROUND: Patients with sarcomatoid renal-cell carcinomas (sRCC) have poor outcomes and limited treatment options. Preclinical and clinical data suggest susceptibility to cytotoxic agents and vascular endothelial growth factor-targeted therapies. We designed a phase 2 trial to evaluate the efficacy and safety of capecitabine, gemcitabine, and bevacizumab in sRCC. PATIENTS AND METHODS: Patients with metastatic or unresectable sRCC were eligible for inclusion. Patients received oral capecitabine 800 mg/m(2) twice daily on days 1 to 21 of a 28-day cycle, intravenous gemcitabine 900 mg/m(2) on days 1 and 15, and intravenous bevacizumab 10 mg/kg on days 1 and 15...
August 10, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28833389/morphological-spectrum-of-renal-cell-carcinoma-unclassified-an-analysis-of-136-cases
#19
Carmen M Perrino, David J Grignon, Sean R Williamson, Muhammad T Idrees, John N Eble, Liang Cheng
AIMS: Renal cell carcinoma, unclassified (RCCU) is a category that includes a morphologically and biologically heterogeneous group of tumours that are unable to be diagnosed as other well-defined entities. We aim to describe the morphological findings of tumours within this category and to determine the most frequent morphological features leading to classification difficulty. METHODS AND RESULTS: One hundred and thirty-six cases of RCCU were examined. Patients ranged in age from 23 to 87 years...
August 18, 2017: Histopathology
https://www.readbyqxmd.com/read/28832979/programmed-cell-death-ligand-1-and-tumor-infiltrating-lymphocyte-status-in-patients-with-renal-cell-carcinoma-and-sarcomatoid-dedifferentiation
#20
Fumi Kawakami, Kanishka Sircar, Jaime Rodriguez-Canales, Bryan M Fellman, Diana L Urbauer, Pheroze Tamboli, Nizar M Tannir, Eric Jonasch, Ignacio I Wistuba, Christopher G Wood, Jose A Karam
BACKGROUND: The immune profile of sarcomatoid renal cell carcinoma (sRCC), including the programmed cell death ligand 1 (PD-L1) and programmed cell death 1 (PD-1) status, has not been well characterized. METHODS: An immunohistochemical digital analysis of PD-L1, PD-1, CD4, and CD8 was performed on nephrectomy specimens from 118 sRCC patients and 92 nonsarcomatoid clear cell renal cell carcinoma (ccRCC) patients. The clinical characteristics of the population were compared between sRCC and ccRCC...
August 22, 2017: Cancer
keyword
keyword
51054
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"